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A Ab bs st tr ra ac ct t
The Genetic Information Nondiscrimination Act of 2008 (GINA) was recently enacted in the
United States. Its supporters have applauded the passage of GINA, and they hope that it will
alleviate public fear about genetic discrimination and facilitate genetic testing and participation in
genetic research. Critics worry that GINA does not provide adequate protection because it fails
to address discrimination on the basis of non-genetic health-related information, and it only
regulates the use of genetic information in health insurance and employment. Despite these
limitations, GINA represents a major step forward in US policy. Additional research is needed to
assess the impact of GINA on industry practice and public opinion. In the mean time, education
about GINA and its limitations can help individuals make more informed decisions about genetic
testing and participation in genetic research.
The Genetic Information Nondiscrimination Act of 2008
(GINA) was signed into US federal law on 21 May 2008 and
will become effective within 12-18 months [1]. The first
genetic nondiscrimination bill was introduced in the US
House of Representatives in 1995. It took 13 years of lobby-
ing from patient advocacy groups, researchers, medical
professional organizations, and commercial interests to
achieve bipartisan support for this type of legislation.
Although many US states have laws that protect against
genetic discrimination [2] and there are some limitations to
the use of genetic information imposed on group health
plans by the Health Insurance Portability and Accountability
Act of 1996 (HIPAA), advances in genetic research have
created an urgency to the passage of more comprehensive
federal legislation. For many, GINA “marks the beginning of
a new era in health care” in which “[i]ndividuals no longer
have to worry about being discriminated against on the basis
of their genetic information” [3].
GINA was designed to protect individuals from discrimi-
nation on the basis of genetic information with respect to
health insurance and employment. Specifically, it prohibits
group and individual health insurers from collecting and
using a person’s genetic information in determining eligi-
bility and premiums, and it limits employers’ ability to
collect genetic information and prohibits them from using
such information in making employment decisions such as
hiring, firing, job assignments, or any other terms of
employment [1]. Genetic information is defined broadly
under GINA and includes information about genetic tests on
individuals and their family members as well as information
about family medical history (the manifestation of a disease
or disorder in family members, including dependents and
first, second, third, and fourth degree relatives). A genetic
test refers to an analysis of human DNA, RNA, chromo-
somes, proteins, or metabolites that detects genotypes,
mutations, or chromosomal changes. Supporters of GINA
have applauded its passage into law and hope that it will
alleviate the public’s concerns about genetic discrimination
[4-6], which many believe have discouraged the utilization of
medically necessary genetic services and participation in
important genetic research [7,8]. Some argue that this fear is
not warranted, citing a lack of documented evidence of
discriminatory practices [9]. Yet, individuals report
experience with genetic discrimination that has a negative
impact on them and their families [10,11], and recent
historical examples include mandated screening for sickle
cell anemia among African Americans [1].
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to the United States, have led to the enactment of genetic
nondiscrimination legislation in many European countries.
Against a backdrop of relatively uniform general laws
protecting the privacy of personal data, these genetics-
focused laws vary considerably from country to country. In
terms of defining genetic information, most of these laws are
less inclusive than GINA in that they tend to leave family
history outside the scope of legal protection [12,13]. In a
recent article [14], Van Hoyweghen and Horstman argue
that, overall, this legislation has been less effective than
hoped in preventing the misuse of genetic information and
allaying public concerns about genetic discrimination, and it
may have the unintended effect of increasing other kinds of
discrimination. The impact of GINA on industry practice and
public opinion in the United States deserves careful
examination and should be a research priority.
Critics assert that GINA is not an optimal policy response to
the concerns it seeks to address because it is not compre-
hensive, in two senses. In the first sense, GINA is not
comprehensive because it does not regulate health insurers’
and employers’ access to and use of all health-related
information, or even all predictive information (that is,
information with possible relevance to future health states).
Someone considering genetic counseling or testing for the
BRCA1 breast cancer associated gene can be assured that,
after GINA takes effect, their prospects for health insurance
or employment will not be affected. No such assurance can
be extended to an individual considering consultation with a
mental health professional or a check of lipid levels. One
aspect of justice is treating similar cases alike. In this
respect, federal law seems to fall short, another instance of
‘genetic exceptionalism’ [15].
The necessity of defining and isolating genetic information
from other kinds of information so that it can receive
exceptional treatment introduces a new problem. As the
scientific case builds for a multifactorial understanding of
most diseases, and as information that has some claim to
being genetic becomes integrated into routine care, any
lines drawn may seem increasingly arbitrary [16,17]. For
example, commentators have expressed some confidence
that cholesterol tests would not be covered by GINA [18].
Yet one might assert, not entirely implausibly, that testing
to determine low density lipoprotein (LDL) levels in
someone suspected of having familial hypercholesterolemia
is a genetic test. GINA provides broad protections for
information about genetic susceptibilities to disease, but it
does not protect information about manifestations of a
disease or disorder in the individual [1]. The response could
therefore be that high levels of LDL in such an individual
would count as the manifestation of a disease or disorder,
even in the absence of any evidence of atherosclerosis, and
so any claim to protection under GINA would be lost for
that reason. This serves to highlight another problem of
where the line is drawn: what counts as a manifestation of a
disease or disorder?
In the United States, the question of GINA and justice is tied
to an underlying problem: the coupling of a widely held belief
that individuals should have access to health care (regardless
of health status and risk, at least to the extent that those
factors are not wholly under their control) and employment
(to the extent they are able to do a job) with a system in which
access to health care is by no means guaranteed and in which
medical underwriting in health insurance has implications
for employment. Because employers are often providers of
health insurance and face medical underwriting at the level of
the whole company, they have reason to care about employee
health for a reason that has nothing to do with job
performance. For small employers, in particular, an employee
with the potential to generate high health-care costs is a
threat to the welfare of the enterprise. GINA reflects rather
than solves this problem. It defines genetic information in
order to make it off limits to health insurers and employers,
preserving access to health-care and employment oppor-
tunities that would otherwise be imperiled by the general
practice of medical underwriting; but it leaves that practice
otherwise unaffected and, at the point of actual illness,
removes any protection from the harsh effects of the current
regime. Some may fear that the passage of GINA will serve as
an escape valve, lessening pressure for broader health-care
reform [19], but it could also be described as a step in the
right direction.
The second sense in which GINA is not comprehensive is
that it fails to address fears about genetic information and
access to other kinds of opportunities or insurance
products, including life, disability, long-term care, and
mortgage insurance [20]. Policy issues related to life
insurance and disability insurance have been studied at
length, and in each area there are complexities that defy a
simple ‘one size fits all’ solution [21,22]. European
countries, less preoccupied with private health insurance,
are ahead of the US in adopting nuanced regulatory
approaches to other kinds of insurance, for example
protecting access to policies in standard amounts and
creating public entities to assess the actuarial validity of
genetic tests [12,13]. If significant sections of the public
focus on these gaps in US policy, reluctant to enter the
genomic era without a blanket guarantee against harm,
GINA may fail to live up to the hopes of its supporters.
Despite these limitations, the passage of GINA is a major
step forward in US policy. For the advocates who have
worked tirelessly for many years to pass GINA and for the
patients, clinicians, and researchers who anticipate its
benefits, this is a time to celebrate, not dwell on
shortcomings. At last US citizens have a floor of protection
across all states and across all categories of core genetic
information, including family history.
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be seen. Clinicians may be more comfortable offering genetic
testing, knowing that the results cannot be used for
employment decisions or to determine eligibility or
premiums in health insurance. Building on GINA, clinicians
and researchers have an opportunity to improve their
counseling of patients and potential research subjects. Given
the patchwork of protections that existed before the passage
of GINA, it would have been excusable to resort to a kind of
warning like that given by police to criminal suspects that
any information that results from this encounter/test/study
may be used against you. It now becomes possible to inform
patients and subjects that all health insurers and the vast
majority of employers in the US will be prohibited from
engaging in certain actions - thereby opening the door to
tailored exploration of the areas of risk that remain (that is,
the types of health-related information and opportunities or
insurance products that are not covered under GINA). If we
do our part in educating about GINA, individuals will be able
to make more informed decisions about genetic testing and
participation in genetic research.
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